Calcium (Ca²⁺) homeostasis is essential for neuronal survival, synaptic transmission, and cellular signaling. Progressive Supranuclear Palsy (PSP), a 4-repeat tauopathy characterized by progressive postural instability, supranuclear gaze palsy, and cognitive decline, involves significant calcium dysregulation that contributes to neuronal vulnerability, tau pathology, and progressive neurodegeneration [1][2]. While calcium dysregulation has been extensively studied in Alzheimer's disease (AD) and Parkinson's disease (PD), emerging evidence specifically links calcium mishandling to the selective vulnerability of brainstem nuclei, basal ganglia, and cortical neurons in PSP [3]. [1]
The precise mechanisms underlying calcium dysregulation in PSP involve multiple interconnected pathways: voltage-gated calcium channel (VGCC) alterations, impaired mitochondrial calcium buffering, endoplasmic reticulum (ER) stress, store-operated calcium entry (SOCE) dysfunction, and excitotoxic mechanisms. These disturbances create a vicious cycle that accelerates tau hyperphosphorylation, aggregation, and propagation while simultaneously promoting neuronal apoptosis. [2]
L-type voltage-gated calcium channels (Cav1.2, encoded by CACNA1C) are prominently expressed in neurons of the substantia nigra, basal ganglia, and brainstem nuclei—regions particularly affected in PSP [4]. Post-mortem studies of PSP brain tissue demonstrate increased L-type channel expression and enhanced calcium influx in vulnerable neuronal populations. This upregulation appears to be a compensatory response to cellular stress, but paradoxically contributes to calcium overload and subsequent neurotoxicity [5]. [3]
The dysregulation of L-type channels in PSP shares similarities with findings in PD, where Cav1.3 (encoded by CACNA1D) channels have been extensively studied. However, PSP demonstrates a distinct pattern with preferential involvement of Cav1.2-containing channels in brainstem motor nuclei [6]. [4]
P/Q-type calcium channels (Cav2.1, encoded by CACNA1A) and N-type channels (Cav2.2, encoded by CACNA1B) regulate neurotransmitter release at synaptic terminals. In PSP, these channels exhibit altered phosphorylation states and trafficking, leading to dysregulated synaptic calcium dynamics. The resulting imbalance between excitatory and inhibitory neurotransmission contributes to the characteristic movement disorders observed in PSP, including bradykinesia, rigidity, and supranuclear gaze palsy [7]. [5]
T-type calcium channels (Cav3.1, Cav3.2, Cav3.3) generate low-threshold calcium spikes important for neuronal excitability. Studies in PSP models demonstrate enhanced T-type channel activity, particularly in subthalamic nucleus neurons. This hyperactivity contributes to abnormal burst firing patterns and network oscillations that underlie the parkinsonian features of PSP [8].
Mitochondria serve as critical calcium buffers, sequestering excess cytosolic calcium during periods of elevated influx. In PSP, multiple factors converge to overwhelm mitochondrial calcium handling capacity:
The mitochondria-associated ER membrane (MAM) is a specialized subdomain where ER and mitochondria form tight contacts, enabling direct calcium transfer. In PSP, tau pathology disrupts MAM integrity, leading to abnormal calcium transfer between these organelles. This disruption creates a bidirectional pathogenic loop: tau accumulation disrupts calcium homeostasis, while calcium dysregulation promotes further tau pathology [9][10].
The Na⁺/Ca²⁺ Exchanger (NCX) and mitochondrial calcium exchangers like NCLX play crucial roles in mitochondrial calcium efflux. Dysfunction of these exchangers in PSP contributes to mitochondrial calcium overload and subsequent bioenergetic failure [11].
Excessive mitochondrial calcium accumulation triggers the mitochondrial permeability transition pore (mPTP), leading to:
This pathway is particularly relevant to PSP because the most vulnerable neurons—those in the substantia nigra pars compacta, subthalamic nucleus, and brainstem raphe nuclei—all demonstrate high basal metabolic demands and corresponding calcium flux [12].
The endoplasmic reticulum (ER) serves as the primary intracellular calcium reservoir. In PSP, ER calcium stores become progressively depleted through multiple mechanisms:
ER calcium depletion triggers the unfolded protein response (UPR), a compensatory mechanism that initially attempts to restore ER homeostasis but becomes maladaptive when prolonged. In PSP, chronic UPR activation leads to:
The GRP78/BiP chaperone system, central to UPR regulation, shows altered expression in PSP brain tissue, reflecting the severity of ER stress in affected regions [13].
When ER calcium stores are depleted, store-operated calcium entry (SOCE) is activated through the STIM1-Orai1 mechanism. STIM1 senses ER calcium depletion and activates plasma membrane Orai1 channels, allowing extracellular calcium influx.
In PSP, chronic ER calcium depletion leads to sustained SOCE activation. While initially protective, prolonged SOCE contributes to:
Excitotoxicity—excessive glutamate receptor activation—represents a major consequence of calcium dysregulation in PSP. The excessive calcium influx through VGCCs and SOCE primes neurons for glutamate-induced excitotoxicity:
Excitotoxicity in PSP differs from that observed in corticobasal syndrome (CBS) in several key aspects:
The CBS vs PSP: Comparative Mechanism Analysis page provides detailed comparison of these related tauopathies.
| Feature | Alzheimer's Disease | PSP |
|---|---|---|
| Primary calcium dysregulation site | Cortical neurons, hippocampus | Brainstem nuclei, basal ganglia |
| Channel focus | L-type, NMDA receptors | P/Q-type, T-type, L-type |
| ER stress | Prominent (Aβ toxicity) | Moderate |
| Mitochondrial dysfunction | Severe | Severe |
| Calcium buffering proteins | Calbindin reduction | Parvalbumin alterations |
While Calcium Dysregulation in Alzheimer's Disease prominently features amyloid-β-mediated toxicity and hippocampal vulnerability, PSP calcium dysregulation is more closely linked to tau pathology and brainstem-selective vulnerability [14].
| Feature | Parkinson's Disease | PSP |
|---|---|---|
| Primary affected region | Substantia nigra pars compacta | Substantia nigra pars reticulata, brainstem |
| Channel focus | L-type (Cav1.3) | Multiple VGCCs |
| Mitochondrial pathway | Complex I deficiency | Multiple complexes |
| Calcium-protein interactions | α-Synuclein | Tau protein |
The Calcium Signaling Dysregulation in Parkinson's Disease page provides comprehensive PD-specific mechanisms. Notably, both PSP and PD involve substantia nigra vulnerability, but the pattern of calcium dysregulation differs in channel subtype involvement and regional distribution [15].
Given the central role of calcium dysregulation in PSP pathogenesis, calcium channel modulators represent rational therapeutic targets:
Drugs targeting mitochondrial calcium handling show potential for PSP:
Reducing ER calcium depletion and UPR activation:
Calcium dysregulation in PSP represents a complex, multifactorial pathology involving:
These mechanisms create a self-perpetuating cycle that accelerates neurodegeneration in PSP-affected brain regions. The comparison with AD and PD reveals both shared features and disease-specific patterns, highlighting the importance of understanding calcium dysregulation as a therapeutic target for PSP and related neurodegenerative disorders.
Pchitskaya & Bezprozvanny, NCLX in neuronal calcium handling (2023). 2023. ↩︎
Choi et al. Mitochondrial calcium overload in PSP (2024). 2024. ↩︎
Hoozemans et al. ER stress in tauopathies (2022). 2022. ↩︎
Bezprozvanny, Calcium signaling and neurodegeneration (2023). 2023. ↩︎
Surmeier et al. Calcium and neurodegeneration in PD and PSP (2024). 2024. ↩︎